10-K/A: Adagio Medical Holdings Files Amendment No. 1 to Form 10-K, Updating Executive and Governance Information

Adagio Medical Holdings files an amendment to its annual report to include information on directors, executive officers, corporate governance, and updated exhibits.

Summary

• Adagio Medical Holdings, Inc. filed Amendment No. 1 to its Annual Report on Form 10-K to include information required by Items 10 through 14 of Part III and to update the exhibit list in Item 15.
• The company's definitive proxy statement will not be filed within 120 days after December 31, 2024, necessitating the inclusion of Part III information in the Form 10-K.
• Item 15 was amended to include new certifications from the principal executive officer and principal financial officer.
• The amendment does not modify or update disclosures in the initial filing from March 27, 2025, and should be read in conjunction with subsequent SEC filings.
• As of April 28, 2025, Adagio Medical Holdings had 15,381,565 shares of common stock outstanding.
• Todd Usen has served as the Chief Executive Officer and a director since December 2024.
• Orly Mishan has served as Chairperson and a director since December 2024.
• Daniel George was appointed as Interim Chief Financial Officer in April 2025.
• The company's common stock began trading on the Nasdaq Capital Market on August 1, 2024.
• The company has adopted a Code of Ethics and Business Conduct applicable to all employees, executive officers, and directors.
• The company maintains a 401(k) retirement savings plan for eligible employees.

Sentiment

Score: 6

Explanation: The document is primarily factual and descriptive, with some negative aspects related to executive departures and below-target performance offset by positive aspects related to leadership appointments and governance policies.

Positives

• The company has appointed experienced individuals to key leadership positions.
• The company has established corporate governance policies, including a Code of Ethics and Business Conduct and an Insider Trading Policy.
• The company offers a 401(k) retirement savings plan for employees.
• The company has an equity incentive plan to align employee and stockholder interests.

Negatives

• The company had several executive departures, including the former President and CEO, Chief Operating Officer, and Chief Financial Officer.
• The company's overall performance in 2024 was below target, resulting in lower bonus amounts for eligible executive officers.
• Lucira Health, Inc., where Daniel George served as CFO, filed for bankruptcy in February 2023.

Risks

• The company's success depends on attracting and retaining qualified personnel.
• The company faces risks associated with compliance with insider trading laws and regulations.
• The company's performance is subject to various factors, including market conditions and competition.

Future Outlook

The company expects to grant additional equity incentive awards to its executives to secure the management team for the long term and align their decision-making with long-term stockholder value.

Industry Context

The document provides insight into the executive compensation and corporate governance practices of a publicly traded medical device company, which is relevant for understanding industry standards and benchmarks.

Comparison to Industry Standards

• The executive compensation packages, including base salaries, bonuses, and equity incentives, are typical for companies of similar size and stage in the medical device industry.
• The board composition and committee structure align with standard corporate governance practices for Nasdaq-listed companies.
• The indemnification agreements for directors and officers are common in Delaware corporations to attract and retain qualified individuals.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The amendment provides updated information on executive compensation and corporate governance, which is relevant for making informed investment decisions.
• Employees: The amendment outlines the company's compensation and benefits programs, as well as its Code of Ethics and Business Conduct.
• Customers: The amendment does not directly impact customers.
• Suppliers: The amendment does not directly impact suppliers.
• Creditors: The amendment does not directly impact creditors.

Next Steps

• The company will continue to execute its business strategy and pursue growth opportunities.
• The company will file its definitive proxy statement at a later date.
• The company will continue to monitor and comply with relevant securities laws and regulations.

Key Dates

Keywords

executive compensation, corporate governance, directors, officers, financial reporting, Adagio Medical Holdings, Form 10-K, amendment